Episode 029: Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

The Filtrate:

Matt Sparks

Jennie Lin

Samira Farouk

Joel Topf

Swapnil Hiremath

And two special guests:

Dawn J. Caster, Assistant Professor at University of Louisville

Alfred Kim, Assistant Professor of Medicine at Washington University (Twitter)

Show Notes:

NephJC coverage of the trial: The Bliss trial

In the NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2001180

Turtles all the way down: https://en.wikipedia.org/wiki/Turtles_all_the_way_down

Nature previews Nephrology on BAFF: https://www.nature.com/articles/nri844

Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial: https://pubmed.ncbi.nlm.nih.gov/29563108/

BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration: https://clinicaltrials.gov/ct2/show/NCT02062684

Guideline for naming monoclonal drugs: https://www.antibodysociety.org/wordpress/wp-content/uploads/2017/07/INN-2017-Reference-20.pdf

A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group: https://pubmed.ncbi.nlm.nih.gov/9541091/

Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis https://pubmed.ncbi.nlm.nih.gov/25757867/

A Day In The Life Of Dr. Anthony Fauci: https://www.huffpost.com/entry/anthony-fauci-fighting-covid-19_n_5fc7fed7c5b61bea2b14e3ee

MC Arbatin MD FPCP FPSN @mcamd: the glomerulus tree: https://twitter.com/mcamd/status/1337744822543605760

finished product: https://twitter.com/mcamd/status/1338429211963322371